Two Penguins Investment
Preparing your financial briefing…
Financial Intelligence
Recent perspective
Recent financial reporting selected by recency, stored importance, and source diversity.
Live chronology
Page 664 · Newest reporting first
Nasdaq Marketscompaniesinvestment opinion
Pepsi trades at a low valuation with a 4.2% dividend yield. Wall Street is favoring Coca-Cola, which has been a consistent performer.
Nasdaq Marketsmarketsroutine announcement
The Sunday edition discusses using an AI assistant to shortlist small-company investment prospects. It highlights a Rule Breakers team approach to identifying opportunities.
Nasdaq Marketscompaniesinvestment opinion
NuScale stock has fallen 83% following a series of negative news developments. The article weighs whether the decline represents a bargain or a value trap.
Nasdaq Marketscompaniesinvestment opinion
Visa is a pure-play payment network with higher profit margins, while American Express also operates as a lender. The article compares the two financial stocks as investment options.
Nasdaq Marketscompaniesearnings
Victoria's Secret stock fell this week despite a substantial earnings beat in fiscal Q2. The decline suggests investor concerns outweighed the positive results.
Nasdaq Marketscompaniescorporate event
Vici Properties raised its dividend by another 2.2%, continuing a trend since its 2018 IPO. The company has the highest dividend yield in the S&P 500.
Nasdaq Marketsmarketsinvestment opinion
The Vanguard Russell 1000 Value ETF holds stocks traditionally labeled as growth names, including Amazon, Apple, and Microsoft. The article predicts Nvidia will join the ETF before year-end.
Nasdaq Marketscompaniesearnings
Palo Alto Networks beat Wall Street's sales and earnings targets for fiscal Q4. The stock still fell sharply this week.
Nasdaq Marketscompaniesearnings
Rezolve AI stock fell this week after the company posted its first-half results. The decline followed the earnings release.
Nasdaq Marketscompaniesinvestment opinion
Moderna has had success with its mRNA vaccine technology. The article compares five-year and one-year investment returns for the stock.